Simultaneous determination of blonanserin and its metabolite in human plasma and urine by liquid chromatography–tandem mass spectrometry: Application to a pharmacokinetic study
Authors:
- Yu-Guan WenYWYu-Guan Wen
- Xiao-Jia NiXNXiao-Jia Ni
- Ming ZhangMZMing Zhang
- Xia LiuXLXia Liu
- De-Wei ShangDSDe-Wei Shang
- 1 August 2012
- journal article
- clinical trial
- Published by Elsevier in Journal of Chromatography B
- Vol. 903, 46-52
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Three cases of schizophrenia showing improvement after switching to blonanserinPsychiatry and Clinical Neurosciences, 2011
- Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonistPharmacology Biochemistry and Behavior, 2010
- Efficacy and Tolerability of Blonanserin in the Patients With SchizophreniaClinical Neuropharmacology, 2010
- Effect of dose timing in relation to food intake on systemic exposure to blonanserinEuropean Journal of Clinical Pharmacology, 2010
- Simple analysis of blonanserin, a novel antipsychotic agent, in human plasma by GC-MSForensic Toxicology, 2010
- BlonanserinCNS Drugs, 2010
- The Efficacy and Safety of Blonanserin Compared with Haloperidol in Acute-Phase SchizophreniaCNS Drugs, 2009
- Pharmacological profiles and clinical effects of blonanserin (Lonasen®) on schizophreniaFolia Pharmacologica Japonica, 2008
- Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agentBioorganic & Medicinal Chemistry Letters, 2005
- Determination of a novel anti-psychotic agent AD-5423 and its metabolites in plasma by high-performance liquid chromatography with fluorescence detectionJournal of Pharmaceutical and Biomedical Analysis, 1997